SCHEMBL15046635

SCHEMBL15046635

Cc1ccc(=O)n(C[C@H](O)C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.50
ALDH1A1 P00352 4/20 0.50
MAPT P10636 2/20 0.50
POLB P06746 1/20 0.50
RXFP1 Q9HBX9 1/20 0.37
KMT2A Q03164 3/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 2/20 0.34
HPGD P15428 1/20 0.34
BLM P54132 1/20 0.34
HSD17B10 Q99714 1/20 0.34
LMNA P02545 2/20 0.33
PTGDR2 Q9Y5Y4 2/20 0.33
HTT P42858 1/20 0.33
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
CETP P11597 1/20 0.32
IDH1 O75874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15046561 1.00 KDM4E (0.50) KDM4EALDH1A1MAPTPOLBRXFP1
SCHEMBL15046620 1.00 KDM4E (0.50) KDM4EALDH1A1MAPTPOLBRXFP1
SCHEMBL15807127 0.81 HTT (0.36) KDM4EALDH1A1MAPTPOLBKMT2A
SCHEMBL15046555 0.81 HTT (0.36) KDM4EALDH1A1MAPTPOLBKMT2A
SCHEMBL16418591 0.81 LMNA (0.38) KDM4EALDH1A1MAPTPOLBRXFP1
SCHEMBL16418600 0.81 LMNA (0.38) KDM4EALDH1A1MAPTPOLBRXFP1
SCHEMBL16418602 0.81 LMNA (0.38) KDM4EALDH1A1MAPTPOLBRXFP1
SCHEMBL15046556 0.81 HTT (0.36) KDM4EALDH1A1MAPTPOLBKMT2A
SCHEMBL14407048 0.80 ALDH1A1 (0.56) KDM4EALDH1A1MAPTPOLBRXFP1
SCHEMBL14407049 0.80 ALDH1A1 (0.56) KDM4EALDH1A1MAPTPOLBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096527-B2 TRPM8 antagonists and their use in treatments AMGEN INC. (US) 2015-08-04 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140171406-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2014-06-19 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 KDM4E 2769/4885ALDH1A1 4469/4885MAPT 727/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 KDM4E 2769/4885ALDH1A1 4469/4885MAPT 727/4885
US-20140171406-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 KDM4E 3641/4885ALDH1A1 4051/4885MAPT 800/4885
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 KDM4E 3641/4885ALDH1A1 4051/4885MAPT 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.